BeyondSpring Pharmaceutical Inc

New York,  NY 
United States
https://www.beyondspringpharma.com/

• Booth: 4097a

BeyondSpring (BYSI) is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies. Its lead asset, Plinabulin, is in two Phase 3 clinical programs: in combination with G-CSF for the prevention of chemotherapy-induced neutropenia (CIN). Plinabulin was granted BREAKTHROUGH status by the US FDA and China NMPA in late 2020 and was recently submitted as a NDA on March 31, 2021. Plinabulin is also in a Phase 3 global clinical trial as a direct anticancer agent in the treatment of NSCLC, with an anticipated topline readout in mid-2021.

Brands: https://events.jspargo.com/ASCO21/CUSTOM/BeyondSpring_ASCO_Banner_1140x250.jpg

 Press Releases

• Launch the BeyondSpring Virtual Experience (Apr 30, 2021)
  https://beyondspring.exhibitcast.net/?utm_source=ASCO%202021&utm_medium=booth&utm_campaign=exhibit%20hall%20link